CDK4/6 Inhibitors Overcome Endocrine ESR1 Mutation-Related Resistance in Metastatic Breast Cancer Patients

SIMPLE SUMMARY: The present study investigates the clinical benefit of CDK4/6i in ESR1 mutant HR+ mBC patients treated with a CDK4/6i as first- or second-line therapy. Plasma was collected at baseline prior to CDK4/6i plus hormone therapy, and ESR1 mutation was analyzed in circulating free DNA by a...

Descripción completa

Detalles Bibliográficos
Autores principales: Crucitta, Stefania, Ruglioni, Martina, Lorenzini, Giulia, Bargagna, Irene, Luculli, Giovanna Irene, Albanese, Irene, Bilancio, Diana, Patanè, Francesca, Fontana, Andrea, Danesi, Romano, Del Re, Marzia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954458/
https://www.ncbi.nlm.nih.gov/pubmed/36831647
http://dx.doi.org/10.3390/cancers15041306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954458/
https://www.ncbi.nlm.nih.gov/pubmed/36831647
http://dx.doi.org/10.3390/cancers15041306

Ejemplares similares